Can-Fite BioPharma Ltd.
CANF
$3.39
$0.030.89%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 405.00K | 482.50K | 560.00K | 617.00K | 674.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 405.00K | 482.50K | 560.00K | 617.00K | 674.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 405.00K | 482.50K | 560.00K | 617.00K | 674.00K |
| SG&A Expenses | 3.66M | 3.63M | 3.59M | 3.32M | 3.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.36M | 9.92M | 9.49M | 9.15M | 8.80M |
| Operating Income | -9.95M | -9.44M | -8.93M | -8.53M | -8.13M |
| Income Before Tax | -9.83M | -9.31M | -8.80M | -8.34M | -7.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.83 | -9.31 | -8.80 | -8.34 | -7.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.83M | -9.31M | -8.80M | -8.34M | -7.88M |
| EBIT | -9.95M | -9.44M | -8.93M | -8.53M | -8.13M |
| EBITDA | -9.93M | -9.42M | -8.91M | -8.51M | -8.12M |
| EPS Basic | -6.59 | -7.76 | -8.94 | -10.05 | -11.17 |
| Normalized Basic EPS | -4.11 | -4.85 | -5.58 | -6.27 | -6.97 |
| EPS Diluted | -6.59 | -7.76 | -8.94 | -10.05 | -11.17 |
| Normalized Diluted EPS | -4.11 | -4.85 | -5.58 | -6.27 | -6.97 |
| Average Basic Shares Outstanding | 6.58M | 5.27M | 3.96M | 3.43M | 2.90M |
| Average Diluted Shares Outstanding | 6.58M | 5.27M | 3.96M | 3.43M | 2.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |